Amy Dykan, controllar at Kingbird Pharmaceutical Industrias, a public company, is currently praparing the caleulation for basic and

diluted earnings per share and the re ated disclosurs for Kingbird's financial statemants. Below is selected financial information for the

facal year ended June $30,2025.$

Sharahalders' equity

The following tranasactions have also occurred at Kingbird.

Options wers granted on July $1,2024,$ to purchase $220,000$ sharss at $$15$ par shars. Although no aptione were exercised

during facal year $2025,$ the averase price per common share during facal year $2025$ was $$20$ per share.

Each bond was issued at face value. The $6\%$ convertible bonds will convart into comman stock at $50$ sharss per $$1,000$ bond.

The bonds are evarcisable after $5$ years and wers issued in fiscal year $2024.$

The prafarred stodkwas issuad in $2024.$

Thare are no praferred dividends in arrears, however, prafarred dividends ware nat declared in figeal year $2025.$

The $990,000$ shars of common stock ware outstanding for the entire $2025$ fiscal year.

Net incame for fiscal year $2025$ was $$1,520,000,$ and the averase income tax rate is $2006$

For the fscal year ended June $30,2025,$ caloulate the following for Kingbird Pharmaceutical Industries. $($Round answers to $2$ decimal

places, e$.$s$.2\mathrm{.}45.)$

a$.$ Basic earnings par share.

Basic earnings per share $

b$.$ Diluted arnings per share.

Diluted aarnins parshars $